Nascent Biotech: This Cancer Research Microcap Has A Drug in Testing with Indications for Use Against COVID-19

As the world of pharma and biotech companies works towards finding a solution for COVID-19, we see a number of different research-oriented companies emerging. Many of these companies specialize in areas that are not related to antiviral drugs, but still have excellent, potential therapies that could well become essential in the fight to cure the coronavirus that has swept the globe over the past few months. One such Company in the oncological research space that is testing a potential usage for the COVID-19, is Nascent Biotech (OTCQB:NBIO).

What Does Nascent Biotech Do?

Nascent Biotech is a clinical-stage biopharmaceutical company focused on cancer research, particularly with respect to cancers that affect the brain. The Company develops human antibodies and cytokine responses for the treatment of various forms of cancer and the antibodies have strong antiviral applications as well. While brain cancers were always the core focus of Nascent Biotech’s research, its monoclonal antibodies are intended to treat malignancies, such as glioblastoma and malignant astrocytoma, lung and breast cancer metastases to the brain, pancreatic cancer, and as importantly, viruses like COVID-19. The Company is headquartered in San Diego, California.

Nascent Biotech’s Research Approach

An antibody is defined as a large, Y-shaped protein that is used by the immune system of the human body in order to recognize the unique molecules of pathogens, whether it is cancer, bacterial, or viral, and to neutralize these pathogens. These antibodies are essentially produced naturally by the human immune system and they form the base of Nascent Biotech’s research. The Company is using and developing human antibodies and cytokine responses obtained from innate natural human immune responses as a drug discovery platform for identifying new antibodies and antigens for commercialization. The Company’s technology portfolio is based upon the natural human immune system, uniquely utilizing the immune system’s innate capabilities and selectivity to produce biomolecules for a more effective disease treatment. Nascent Biotech’s researchers believe that the natural immune response enables the rapid development of new classes of safe, non-toxic and specific biological drugs for use in the clinic. The potential indications for this kind of technology and research are not only in the field of oncology but also for various infectious pathogens like SARS-CoV-2, the coronavirus that causes COVID-19.

Strong Track Record in Cancer Research

Nascent Biotech has an excellent track record in cancer research. The Company has already received FDA clearance to begin Phase 1 of human trials for brain cancer and has an approved IRB to begin these trials.  Pritumumab has received the Orphan Drug Designation for both brain cancer as well as pancreatic cancers. In addition to brain cancers, the Company’s research has a strong application in various forms of cancer therapies for lung cancer, breast cancer, colon cancer. The Company’s product is already licensed for the Chinese market for a duration of 20 years with 9% royalty upon commercial approval. 

PTB Antibody – Cancer Applications

Pritumumab is the Company’s lead therapeutic asset and the result of many years of successful research. PTB is essentially a natural human antibody that was derived from a B-cell isolated from a tumor draining lymph node of a patient with cervical cancer. It has been previously tested on 249 human brain cancer patients in Japan. The results indicated that there was a tumor response even at very low doses. PTB’s key preclinical development and toxicology studies for the U.S. are complete and the Company received partial FDA clearance in December 2018 to begin Phase 1 human trials in the U.S. for brain cancer. The product has a large addressable market and Nascent has already manufactured it on a commercial scale. 

Can PTB Become the Game Changer in The Current COVID-19 Crisis?

PTB’s application is not restricted to cancer alone and it may have the ability to counter coronaviruses like the Severe Acute Respiratory Syndrome (SARS), the Middle East Respiratory Syndrome (MERS), and COVID-19, which is currently the cause of a global pandemic. The target protein, cell-surface vimentin, to which PTB binds.    PTB is being studied to confirm whether or not it may block the ability of the virus to recognize, and therefore infect, its target cells. This could make it possible for PTB to be of excellent use in the fight against various viral infections and opens a new direction for Nascent Biotech in the development of novel antiviral drugs for the treatment of coronaviruses like COVID-19. It is worth highlighting the criticality of surface vimentin for the cell entry of coronaviruses as described by Yu et. al., in the Journal of Biomedical Science in 2016, long before the COVID-19 became a worldwide concern. Their research details how Vimentin interacts directly with the SARS coronavirus during its binding process to the non-infected cell and that anti-vimentin antibodies (like the PTB in our context) diminished the uptake of the SARS Coronavirus in pre-treated animals. This implies the huge potential of PTB in the current COVID-19 scenario.

Key Takeaways

While Nascent Biotech is a research-focused, zero-revenue microcap, the inherent risk associated with it is significantly lower than other biotech microcaps. The Company’s annual cash burn is close to $1 million which is nominal. Also, PTB has a proven manufacturing process and demonstrated safety in toxicology studies. The Company’s base of intellectual property is strong, and it is poised to grow, with the work on the COVID-19 therapy progressing rapidly. With the FDA moving promising Covid-19 therapies through the regulatory process, it is just a matter of time before Nascent may have a drug candidate for human trials.

---

Disclaimer

Except for the historic info introduced herein, issues mentioned on this article include forward-looking statements which can be topic to sure dangers and uncertainties that might trigger precise outcomes to vary materially from any future outcomes, efficiency or achievements expressed or implied by such statements. Salesparq, LLC which owns SmallcapsDaily.com isn’t registered with any monetary or securities regulatory authority and doesn’t present nor claims to supply funding recommendation or suggestions to readers of this launch. Salesparq, LLC, which owns SmallcapsDaily.com, could also be compensated for its companies within the type of cash-based compensation for the businesses it writes about. For making particular funding selections, readers ought to search their very own recommendation. Pursuant to an settlement between TraDigital IR and Salesparq, LLC, which owns SmallcapsDaily.com, we have been employed for a interval from 4/1/2020 – 4/30/2020 to publicly disseminate details about Nascent Biotech Inc., together with on the Website, e mail and different media together with Facebook and Twitter. We have been paid twenty thousand dollars for & have been paid “0” shares of restricted frequent shares. We personally own zero shares of Nascent Biotech, Inc. We don’t intend to purchase or promote further shares of Nascent Biotech, Inc. within the open market at any time, together with earlier than, throughout or after the Website and Information, present public dissemination of favorable Information. Please read our full disclaimer found here: https://smallcapsdaily.com/disclaimer/

Disclaimer

This website is a wholly owned subsidiary of SCD Media, LLC, herein referred to as Smallcaps Daily. Our publications are a commercial advertisement and are for general information purposes ONLY. We are engaged in the business of marketing and advertising companies for monetary compensation. We may receive compensation for this article on a PPC basis as an affiliate. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. The disclaimer is to be read and fully understood before using our services, joining our site or our email/blog list as well as any social networking platforms we may use. PLEASE NOTE WELL: Smallcaps Daily and its employees are not a Registered Investment Advisor, Broker Dealer or a member of any association for other research providers in any jurisdiction whatsoever.Release of Liability: Through use of this website viewing or using you agree to hold Smallcaps Daily, its operators owners and employees harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damage (monetary or otherwise), or injury (monetary or otherwise) that you may incur. The information contained herein is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. Smallcaps Daily encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled, or is available from public sources and Smallcaps Daily makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies. None of the materials or advertisements herein constitute offers or solicitations to purchase or sell securities of the companies profiled herein and any decision to invest in any such company or other financial decisions should not be made based upon the information provided herein. Instead Smallcaps Daily strongly urges you conduct a complete and independent investigation of the respective companies and consideration of all pertinent risks. Readers are advised to review SEC periodic reports: Forms 10-Q, 10K, Form 8-K, insider reports, Forms 3, 4, 5 Schedule 13D. Smallcaps Daily is compliant with the Can Spam Act of 2003. Salesparq, LLC does not offer such advice or analysis, and Smallcaps Daily further urges you to consult your own independent tax, business, financial and investment advisors. Investing in micro-cap and growth securities is highly speculative and carries and extremely high degree of risk. It is possible that an investors investment may be lost or impaired due to the speculative nature of the companies profiled. The Private Securities Litigation Reform Act of 1995 provides investors a safe harbor in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact may be forward looking statements. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements indicating certain actions & quote; may, could, or might occur. Understand there is no guarantee past performance will be indicative of future results.In preparing this publication, Smallcaps Daily, has relied upon information supplied by its customers, publicly available information and press releases which it believes to be reliable; however, such reliability cannot be guaranteed. Investors should not rely on the information contained in this website. Rather, investors should use the information contained in this website as a starting point for doing additional independent research on the featured companies. Smallcaps Daily has not been compensated for this article. The advertisements in this website are believed to be reliable, however, Smallcaps Daily and its owners, affiliates, subsidiaries, officers, directors, representatives and agents disclaim any liability as to the completeness or accuracy of the information contained in any advertisement and for any omissions of materials facts from such advertisement. Smallcaps Daily is not responsible for any claims made by the companies advertised herein, nor is Smallcaps Daily responsible for any other promotional firm, its program or its structure. Smallcaps Daily is not affiliated with any exchange, electronic quotation system, the Securities Exchange Commission or FINRA.